1. Home
  2. SWKH vs ELTX Comparison

SWKH vs ELTX Comparison

Compare SWKH & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SWK Holdings Corporation

SWKH

SWK Holdings Corporation

HOLD

Current Price

$15.90

Market Cap

198.4M

Sector

Finance

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$10.52

Market Cap

198.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWKH
ELTX
Founded
1996
2011
Country
United States
United States
Employees
9
N/A
Industry
Diversified Financial Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.4M
198.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SWKH
ELTX
Price
$15.90
$10.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$18.00
$18.00
AVG Volume (30 Days)
104.8K
117.1K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.18
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.32
$4.89
52 Week High
$17.90
$14.93

Technical Indicators

Market Signals
Indicator
SWKH
ELTX
Relative Strength Index (RSI) 32.19 43.89
Support Level $14.69 $9.99
Resistance Level $17.08 $11.23
Average True Range (ATR) 0.37 0.89
MACD -0.05 -0.16
Stochastic Oscillator 12.06 11.42

Price Performance

Historical Comparison
SWKH
ELTX

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: